{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:13:53Z","timestamp":1756901633918,"version":"3.44.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372779","82273083"],"award-info":[{"award-number":["82372779","82273083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Existing studies examining the relationships among immunological cell phenotype, plasma metabolites, and pancreatic cancer susceptibility are limited. More comprehensive research is required to elucidate the complex interactions underlying these associations. Genetic instruments for 731 immune phenotypes (N = 3,757), 1,400 circulating metabolites (N = 8,299), and pancreatic cancer (N = 1,196) were derived from a genome-wide association study (GWAS) meta-analysis. A two-step, two-sample Mendelian randomization (MR) study using the Inverse Variance Weighted method was conducted to investigate the causal influence of immune cell phenotypes on pancreatic cancer and to assess the intermediary role of circulating metabolites. Sensitivity analyses were carried out to verify the robustness, potential heterogeneity, and pleiotropy. MR analyses identified protective effects of CD64 on monocyte (OR = 0.859, 95%CI: 0.802 to 0.920, P = 1.65 \u00d7 10\u22125, PBonferroni = 0.012) against pancreatic cancer. Moreover, 68 metabolites were suggestively associated with pancreatic cancer. Notably, mediation MR revealed that the causal role of CD64 on monocytes in pancreatic cancer was largely mediated by 1-palmitoleoylglycerol (16:1) level (OR = 0.0089, 95%CI: 0.00121 to 0.0167, P = 0.023), accounting for 5.91% of the total effect. These findings establish a causal relationship between CD64 on monocytes and pancreatic cancer, possibly operating through circulating metabolites. The research advances knowledge of the interplay between immune responses and the risk of pancreatic cancer, providing important implications for immunologically targeted treatment approaches.<\/jats:p>","DOI":"10.1093\/jleuko\/qiaf120","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T18:52:33Z","timestamp":1755197553000},"source":"Crossref","is-referenced-by-count":0,"title":["Causal relationships between immunophenotypes, plasma metabolites, and pancreatic cancer: a mediation Mendelian randomization study"],"prefix":"10.1093","volume":"117","author":[{"given":"Jiawei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Immunology, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy , Tianjin 300060 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy , Tianjin 300060 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Bie","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy , Tianjin 300060 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy , Tianjin 300060 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihui","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy , Tianjin 300060 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-2049","authenticated-orcid":false,"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Prevention and Therapy , Tianjin 300060 ,","place":["China"]},{"name":"Key Laboratory of Cancer Immunology and Biotherapy , Tianjin 300060 ,","place":["China"]},{"name":"Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital , Tianjin 300060 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025082903465461600_qiaf120-B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025082903465461600_qiaf120-B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s2468-1253(23)00366-7","article-title":"Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025082903465461600_qiaf120-B3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1042\/ebc20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem"},{"key":"2025082903465461600_qiaf120-B4","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1158\/0008-5472.Can-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"2025082903465461600_qiaf120-B5","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082903465461600_qiaf120-B6","doi-asserted-by":"publisher","first-page":"11160","DOI":"10.3748\/wjg.v20.i32.11160","article-title":"Complex role for the immune system in initiation and progression of pancreatic cancer","volume":"20","author":"Inman","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025082903465461600_qiaf120-B7","doi-asserted-by":"publisher","first-page":"1081919","DOI":"10.3389\/fimmu.2022.1081919","article-title":"Innate immunity in pancreatic cancer: lineage tracing and function","volume":"13","author":"Ye","year":"2022","journal-title":"Front Immunol"},{"key":"2025082903465461600_qiaf120-B8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.Cir-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2025082903465461600_qiaf120-B9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"2025082903465461600_qiaf120-B10","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"2025082903465461600_qiaf120-B11","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2025082903465461600_qiaf120-B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00262-013-1485-8","article-title":"Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy","volume":"63","author":"Bazhin","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2025082903465461600_qiaf120-B13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/PPO.0b013e31829da0ae","article-title":"Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics","volume":"19","author":"Finke","year":"2013","journal-title":"Cancer J"},{"key":"2025082903465461600_qiaf120-B14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd.2016.32","article-title":"Emerging applications of metabolomics in drug discovery and precision medicine","volume":"15","author":"Wishart","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2025082903465461600_qiaf120-B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-pharmtox-010611-134748","article-title":"Xenobiotic metabolomics: major impact on the metabolome","volume":"52","author":"Johnson","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025082903465461600_qiaf120-B16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"2025082903465461600_qiaf120-B17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/ng.3809","article-title":"Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites","volume":"49","author":"Long","year":"2017","journal-title":"Nat Genet"},{"key":"2025082903465461600_qiaf120-B18","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/asn.2016010098","article-title":"Mendelian randomization as an approach to assess causality using observational data","volume":"27","author":"Sekula","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025082903465461600_qiaf120-B19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"2025082903465461600_qiaf120-B20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/2159-8290.Cd-22-1220","article-title":"The DNA damage response and inflammation in cancer","volume":"13","author":"Klapp","year":"2023","journal-title":"Cancer Discov"},{"key":"2025082903465461600_qiaf120-B21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-024-12014-1","article-title":"Assessing the causal relationship between 731 immunophenotypes and the risk of lung cancer: a bidirectional Mendelian randomization study","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"key":"2025082903465461600_qiaf120-B22","doi-asserted-by":"publisher","first-page":"114271","DOI":"10.1016\/j.intimp.2025.114271","article-title":"Untangling immune cell contributions in the progression from GERD to Barrett's esophagus and esophageal cancer: insights from genetic causal analysis","volume":"150","author":"Zhang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2025082903465461600_qiaf120-B23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/js9.0000000000001840","article-title":"The association between immune cells and breast cancer: insights from Mendelian randomization and meta-analysis","volume":"111","author":"Xu","year":"2025","journal-title":"Int J Surg"},{"key":"2025082903465461600_qiaf120-B24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-025-13701-3","article-title":"Assessing the causal association between 731 immunophenotypes and the risk of colorectal cancer: a Mendelian randomization study","volume":"25","author":"Gao","year":"2025","journal-title":"BMC Cancer"},{"key":"2025082903465461600_qiaf120-B25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12916-024-03272-8","article-title":"Plasma metabolites and risk of seven cancers: a two-sample Mendelian randomization study among European descendants","volume":"22","author":"Chen","year":"2024","journal-title":"BMC Med"},{"key":"2025082903465461600_qiaf120-B26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","article-title":"Meta-analysis and Mendelian randomization: a review","volume":"10","author":"Bowden","year":"2019","journal-title":"Res Synth Methods"},{"key":"2025082903465461600_qiaf120-B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41588-022-01270-1","article-title":"Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases","volume":"55","author":"Chen","year":"2023","journal-title":"Nat Genet"},{"key":"2025082903465461600_qiaf120-B28","doi-asserted-by":"publisher","first-page":"1341292","DOI":"10.3389\/fonc.2024.1341292","article-title":"A Mendelian analysis of the relationships between immune cells and breast cancer","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"2025082903465461600_qiaf120-B29","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"2025082903465461600_qiaf120-B30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.aucc.2010.03.001","article-title":"Statistical and clinical significance, and how to use confidence intervals to help interpret both","volume":"23","author":"Fethney","year":"2010","journal-title":"Aust Crit Care"},{"key":"2025082903465461600_qiaf120-B31","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1038\/ncomms7866","article-title":"Structural basis for binding of human IgG1 to its high-affinity human receptor Fc\u03b3RI","volume":"6","author":"Kiyoshi","year":"2015","journal-title":"Nat Commun"},{"key":"2025082903465461600_qiaf120-B32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/imr.12346","article-title":"Structural mechanism of high affinity Fc\u03b3RI recognition of immunoglobulin G","volume":"268","author":"Lu","year":"2015","journal-title":"Immunol Rev"},{"key":"2025082903465461600_qiaf120-B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.cellbio.12.1.181","article-title":"Fc receptors and their interactions with immunoglobulins","volume":"12","author":"Raghavan","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2025082903465461600_qiaf120-B34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1074-7613(02)00294-7","article-title":"FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection","volume":"16","author":"Ioan-Facsinay","year":"2002","journal-title":"Immunity"},{"key":"2025082903465461600_qiaf120-B35","doi-asserted-by":"publisher","first-page":"112797","DOI":"10.1016\/j.celrep.2023.112797","article-title":"T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity","volume":"42","author":"Cui","year":"2023","journal-title":"Cell Rep"},{"key":"2025082903465461600_qiaf120-B36","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.7150\/thno.48868","article-title":"Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"2025082903465461600_qiaf120-B37","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1158\/0008-5472.Can-13-0308","article-title":"Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"2025082903465461600_qiaf120-B38","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.Ccr-21-4383","article-title":"Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025082903465461600_qiaf120-B39","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2025082903465461600_qiaf120-B40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025082903465461600_qiaf120-B41","doi-asserted-by":"publisher","first-page":"1431261","DOI":"10.3389\/fimmu.2024.1431261","article-title":"Metabolite, immunocyte phenotype, and lymphoma: a Mendelian randomization study","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"2025082903465461600_qiaf120-B42","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.7150\/jca.102760","article-title":"Causal relationships between immune cells, plasma metabolites and lung adenocarcinoma: a two-step, two-sample Mendelian randomization study","volume":"15","author":"Zhou","year":"2024","journal-title":"J Cancer"},{"key":"2025082903465461600_qiaf120-B43","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00586-025-08850-9","article-title":"Tracing the pathways: how inflammatory cytokines and blood metabolites drive intervertebral disc degeneration","volume":"34","author":"Liu","year":"2025","journal-title":"Eur Spine J"},{"key":"2025082903465461600_qiaf120-B44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2337\/dc19-2533","article-title":"Microbiota-related metabolites and the risk of type 2 diabetes","volume":"43","author":"Vangipurapu","year":"2020","journal-title":"Diabetes Care"},{"key":"2025082903465461600_qiaf120-B45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","article-title":"CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4","volume":"40","author":"Liao","year":"2022","journal-title":"Cancer Cell"},{"key":"2025082903465461600_qiaf120-B46","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","article-title":"The endocannabinoid system: a potential target for the treatment of various diseases","volume":"22","author":"Lowe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025082903465461600_qiaf120-B47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2025082903465461600_qiaf120-B48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/biom14010116","article-title":"Potential causal association between plasma metabolites, immunophenotypes, and female reproductive disorders: a two-sample Mendelian randomization analysis","volume":"14","author":"Shen","year":"2024","journal-title":"Biomolecules"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jleukbio\/advance-article-pdf\/doi\/10.1093\/jleuko\/qiaf120\/64046309\/qiaf120.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/117\/8\/qiaf120\/64046309\/qiaf120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/117\/8\/qiaf120\/64046309\/qiaf120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:46:56Z","timestamp":1756453616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/doi\/10.1093\/jleuko\/qiaf120\/8234550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jleuko\/qiaf120","relation":{},"ISSN":["1938-3673"],"issn-type":[{"type":"electronic","value":"1938-3673"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8]]},"article-number":"qiaf120"}}